Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
131 studies found for:    c-Met
Show Display Options
Rank Status Study
1 Active, not recruiting cMet CAR RNA T Cells Targeting Breast Cancer
Conditions: Metastatic Breast Cancer;   Triple Negative Breast Cancer
Intervention: Biological: cMet RNA CAR T cells
2 Unknown  Prognostic Value and Clinical Pathology of c-MET Expression and Amplification in Gastric Carcinoma
Condition: Gastric Cancer
Intervention:
3 Not yet recruiting A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors.
Condition: cMET Dysegulation Advanced Solid Tumors
Intervention: Drug: INC280
4 Recruiting A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors
Condition: cMET-dysregulated Advanced Solid Tumors
Interventions: Drug: INC280;   Drug: Midazolam;   Drug: Caffeine
5 Completed
Has Results
A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
Interventions: Drug: PF-02341066;   Drug: PF-00299804
6 Recruiting A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors
Condition: cMET-dysregulated Advanced Solid Tumors
Interventions: Drug: INC280;   Drug: digoxin;   Drug: rosuvastatin
7 Withdrawn Pilot Test of Computerized MET to Reduce Adolescent Alcohol Use
Condition: Alcohol Abuse
Interventions: Behavioral: cASBI+cMET;   Behavioral: cASBI
8 Recruiting Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)
Conditions: Prostate Cancer;   Renal Cell Carcinoma;   Bladder Cancer;   Colorectal Cancer;   Gastric Cancer;   Pancreatic Cancer;   Non-small Cell Lung Cancer;   Advanced MET Amplified Solid Tumor
Interventions: Device: Mesenchymal-marker based ferrofluid (c-MET);   Device: Epithelial cell adhesion molecule (EpCAM) ferrofluid
9 Recruiting Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With Advanced Non-small Cell Lung Cancer Who Have Received One or Two Prior Lines of Therapy
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Drug: INC280 (capmatinib)
10 Active, not recruiting Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy
Conditions: Squamous Cell Carcinoma of Head and Neck,;   Metastatic Colorectal Cancer
Interventions: Drug: INC280;   Drug: cetuximab
11 Recruiting A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy
Condition: c-MET Positive Gastric Cancer
Intervention: Drug: crizotinib
12 Unknown  A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response
Conditions: Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Recurrent
Intervention:
13 Not yet recruiting Pilot Viability of 11C-MET-PET as a Post-surgery Baseline Scan in High-grade Gliomas
Condition: Glioblastoma
Intervention:
14 Recruiting Computer Adaptation of Screening, Brief MET Intervention to Reduce Teen Drinking
Conditions: Alcohol Abuse;   Tobacco Use Disorder;   Substance Use
Intervention: Behavioral: cMET
15 Recruiting 11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues
Condition: Primary Hyperparathyroidism
Interventions: Radiation: 11C-Methionine PET/CT scanning;   Radiation: 18F-FDG PET/CT scanning;   Radiation: SPECT-CT scanning
16 Recruiting A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer
Conditions: Non-Small Cell Lung Cancer (ALK-positive);   Non-Small Cell Lung Cancer (c-Met Dependent);   Non-Small Cell Lung Cancer (ROS Marker Positive);   Systemic Anaplastic Large-Cell Lymphoma;   Advanced Malignancies (Except Leukemia)
Interventions: Drug: PF-02341066;   Drug: Rifampin;   Drug: Itraconazole
17 Active, not recruiting A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment
Condition: Non-small Cell Lung Cancer
Intervention: Drug: INC280
18 Not yet recruiting Visualising c-MET and Activated Neutrophils in Lung Cancer
Condition: Lung Cancer
Interventions: Other: Optical Imaging Agents (EMI-137, NAP);   Device: Delivery Device Cathetar and Miniaturised imaging fibre;   Device: Optical endomicroscopy system
19 Active, not recruiting Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
Condition: Solid Tumors
Intervention: Drug: INC280
20 Recruiting LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Conditions: Urinary Bladder Neoplasms;   Ureteral Neoplasms;   Urethral Neoplasms
Intervention: Drug: Crizotinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.